Tango Therapeutics, Inc. (NASDAQ: TNGX) announced today that it will present first clinical data on its novel CoREST inhibitor TNG260 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025, scheduled for November 5‑9, 2025 in National Harbor, Maryland.
The presentation will include three poster abstracts: Abstract #561 titled “A Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TNG260 in combination with pembrolizumab in patients with STK11‑mutated advanced solid tumors” presented by Dr. Salman R. Punekar; Abstract #681 titled “TNG260, a novel small‑molecule CoREST inhibitor, sensitizes STK11‑mutant tumors to anti‑PD‑1 therapy” presented by Dr. Leanne Ahronian; and Abstract #1225 titled “Inhibition of MGAT1 overcomes STK11‑driven immune evasion in non‑small cell lung cancer.” The Phase 1/2 trial is in the dose‑expansion phase, enrolling patients with STK11‑mutant/RAS‑wild‑type lung cancer, which represents roughly 10 % of lung adenocarcinoma cases.
This marks the first public presentation of clinical data for TNG260, a first‑in‑class CoREST inhibitor being evaluated in combination with pembrolizumab. The data will provide early evidence of safety, tolerability, pharmacokinetics, and preliminary efficacy, informing future trial design and regulatory strategy for the program.
By showcasing these results at a major oncology conference, Tango aims to increase visibility among clinicians and investors, potentially influencing the perception of its precision‑oncology pipeline and supporting future development milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.